GB0316176D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number: GB0316176D0
Authority: GB; United Kingdom
Prior art keywords: combination therapy; therapy; combination
Prior art date: 2003-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GB0316176A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-10

Filing date

2003-07-10

Publication date

2003-08-13

2003-07-10 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

2003-07-10 Priority to GB0316176A priority Critical patent/GB0316176D0/en

2003-08-13 Publication of GB0316176D0 publication Critical patent/GB0316176D0/en

2004-07-07 Priority to CA2531862A priority patent/CA2531862C/en

2004-07-07 Priority to CNB2004800257388A priority patent/CN100425240C/en

2004-07-07 Priority to AT04743275T priority patent/ATE478671T1/en

2004-07-07 Priority to US10/563,668 priority patent/US20060167027A1/en

2004-07-07 Priority to KR1020127017256A priority patent/KR20120093411A/en

2004-07-07 Priority to JP2006518352A priority patent/JP2007526886A/en

2004-07-07 Priority to EP04743275A priority patent/EP1648465B1/en

2004-07-07 Priority to AU2004255022A priority patent/AU2004255022B2/en

2004-07-07 Priority to BRPI0412426-0A priority patent/BRPI0412426A/en

2004-07-07 Priority to DE602004028834T priority patent/DE602004028834D1/en

2004-07-07 Priority to MXPA06000114A priority patent/MXPA06000114A/en

2004-07-07 Priority to ES04743275T priority patent/ES2349194T3/en

2004-07-07 Priority to NZ544458A priority patent/NZ544458A/en

2004-07-07 Priority to KR1020067000464A priority patent/KR20060033782A/en

2004-07-07 Priority to PCT/GB2004/002932 priority patent/WO2005004870A1/en

2005-12-27 Priority to IL172853A priority patent/IL172853A/en

2006-01-09 Priority to ZA200600186A priority patent/ZA200600186B/en

2006-01-20 Priority to NO20060307A priority patent/NO333122B1/en

2006-09-06 Priority to HK06109909.5A priority patent/HK1089378A1/en

2009-11-24 Priority to US12/624,760 priority patent/US20100215773A1/en

2011-11-10 Priority to US13/294,152 priority patent/US20120263802A1/en

Status Ceased legal-status Critical Current

Links

GB0316176A 2003-07-10 2003-07-10 Combination therapy Ceased GB0316176D0 (en)

Priority Applications (22)

Application Number	Priority Date	Filing Date	Title
GB0316176A GB0316176D0 (en)	2003-07-10	2003-07-10	Combination therapy
PCT/GB2004/002932 WO2005004870A1 (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
DE602004028834T DE602004028834D1 (en)	2003-07-10	2004-07-07	USE OF THE CHINAZOLIN DERIVATIVE ZD6474 IN COMBINATION WITH PLATIN COMPOUNDS AND OPTIONALLY IONIZED RADIATION IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND / OR INCREASED VASPERMEABILITY
ES04743275T ES2349194T3 (en)	2003-07-10	2004-07-07	USE OF QUINAZOLINE DERIVATIVE ZD6474 COMBINED WITH PLATINUM COMPOUNDS AND OPTIONALLY IONIZING RADIATION IN THE TREATMENT OF DISEASES ASSOCIATED WITH INCREASED ANGIOGENESIS AND / OR VASCULAR PERMEABILITY.
AT04743275T ATE478671T1 (en)	2003-07-10	2004-07-07	USE OF THE QUINAZOLINE DERIVATIVE ZD6474 IN COMBINATION WITH PLATINUM COMPOUNDS AND OPTIONAL IONIZING RADIATION IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND/OR INCREASED VASCULAR PERMEABILITY
US10/563,668 US20060167027A1 (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR1020127017256A KR20120093411A (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP2006518352A JP2007526886A (en)	2003-07-10	2004-07-07	Use of quinazoline derivative ZD6474 in combination with platinum-based antitumor agents and optional ionizing radiation in the treatment of diseases associated with angiogenesis and / or increased vascular permeability
EP04743275A EP1648465B1 (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2004255022A AU2004255022B2 (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
BRPI0412426-0A BRPI0412426A (en)	2003-07-10	2004-07-07	use of zd6474 or a pharmaceutically acceptable salt thereof and a platinum antitumor agent, pharmaceutical composition, kit, and method for producing an antiangiogenic and / or vascular permeability reducing effect in a warm-blooded animal
CA2531862A CA2531862C (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MXPA06000114A MXPA06000114A (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability.
CNB2004800257388A CN100425240C (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeabi
NZ544458A NZ544458A (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR1020067000464A KR20060033782A (en)	2003-07-10	2004-07-07	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
IL172853A IL172853A (en)	2003-07-10	2005-12-27	Use of the quinazoline derivative zd6474 combined with a platinum anti tumor agent in the manufacture of medicaments for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm blooded animal and pharmaceutical compositions and kits comprising such combination
ZA200600186A ZA200600186B (en)	2003-07-10	2006-01-09	Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of deseases associated with angiogenesis and/or increased vascular permeability
NO20060307A NO333122B1 (en)	2003-07-10	2006-01-20	Use of 4- (4-bromo-2-fluoroanilino) -6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline in combination with platinum compounds in the manufacture of drugs to produce an anticancer or antitumor effect in a warm-blooded animal said as a human as well as pharmaceutical preparation containing the same
HK06109909.5A HK1089378A1 (en)	2003-07-10	2006-09-06	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US12/624,760 US20100215773A1 (en)	2003-07-10	2009-11-24	Use of Quinazoline Derivative ZD6474 Combined With Platinum Compounds and Optionally Ionising Radiation in the Treatment of Diseases Associated With Angiogenesis and/or Increased Vascular Permeability
US13/294,152 US20120263802A1 (en)	2003-07-10	2011-11-10	Use of Quinazoline Derivative ZD6474 Combined With Platinum Compounds and Optionally Ionising Radiation in the Treatment of Diseases Associated With Angiogenesis and/or Increased Vascular Permeability

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB0316176A GB0316176D0 (en)	2003-07-10	2003-07-10	Combination therapy

Publications (1)

Publication Number	Publication Date
GB0316176D0 true GB0316176D0 (en)	2003-08-13

Family

ID=27741942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB0316176A Ceased GB0316176D0 (en)	2003-07-10	2003-07-10	Combination therapy

Country Status (4)

Country	Link
CN (1)	CN100425240C (en)
ES (1)	ES2349194T3 (en)
GB (1)	GB0316176D0 (en)
ZA (1)	ZA200600186B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
EP1244647B1 (en) *	1999-11-05	2006-06-21	AstraZeneca AB	Quinazoline derivatives as vegf inhibitors

2003
- 2003-07-10 GB GB0316176A patent/GB0316176D0/en not_active Ceased
2004
- 2004-07-07 CN CNB2004800257388A patent/CN100425240C/en not_active Expired - Fee Related
- 2004-07-07 ES ES04743275T patent/ES2349194T3/en not_active Expired - Lifetime
2006
- 2006-01-09 ZA ZA200600186A patent/ZA200600186B/en unknown

Also Published As

Publication number	Publication date
ES2349194T3 (en)	2010-12-28
ZA200600186B (en)	2007-04-25
CN1849124A (en)	2006-10-18
CN100425240C (en)	2008-10-15

Legal Events

Date	Code	Title	Description
2004-10-20	AT	Applications terminated before publication under section 16(1)

Publication	Publication Date	Title
GB0307918D0 (en)	2003-05-14	Therapeutic use
GB0303910D0 (en)	2003-03-26	Therapeutic agents
GB0308318D0 (en)	2003-05-14	Therapeutic agents
GB0313250D0 (en)	2003-07-16	Therapeutic agents
GB0218526D0 (en)	2002-09-18	Combination therapy
GB0326486D0 (en)	2003-12-17	Combination treatment
GB0314261D0 (en)	2003-07-23	Therapeutic agents
GB0311859D0 (en)	2003-06-25	Therapeutic agents
GB0311201D0 (en)	2003-06-18	Therapeutic agents
GB0301350D0 (en)	2003-02-19	Therapeutic agents
GB0304524D0 (en)	2003-04-02	Therapeutic agents
GB0303289D0 (en)	2003-03-19	Combination therapy
GB0325021D0 (en)	2003-12-03	Therapeutic combinations
GB0314097D0 (en)	2003-07-23	Combination therapy
GB0329512D0 (en)	2004-01-28	Combination therapy
GB0318311D0 (en)	2003-09-10	Combination therapy
GB0316184D0 (en)	2003-08-13	Combination therapy
GB0316181D0 (en)	2003-08-13	Combination therapy
GB0314100D0 (en)	2003-07-23	Combination therapy
GB0316176D0 (en)	2003-08-13	Combination therapy
GB0307560D0 (en)	2003-05-07	Combination therapy
GB0313363D0 (en)	2003-07-16	Therapeutic combinations
GB0212396D0 (en)	2002-07-10	Combination therapy
GB0208680D0 (en)	2002-05-29	Combination therapy
GB0218388D0 (en)	2002-09-18	Combination therapy